The uncontrolled activation of RAS has an important role in the development of cardiac hypertrophy, the ACE inhibitors being important treatment options, since ACE is an important component of RAS, which leads to the formation of angiotensin II, the main vasoconstrictor of RAS, and to the reduction of baroreflex sensibility for rising blood pressure and sympathetic regulation [81,82]. This evidence concerns the gene ACE and cardiac hypertrophy.